Omeq Medical

Omeq Medical is developing a single-use, smart epidural needle system for safe, accurate epidural injections.

The Product & Advantages

Attached to a standard epidural needle, a special blunted probe repeatedly monitors the dynamic forces exerted by the surrounding tissues and accurately detects needle penetration into the epidural space. Once successful positioning is confirmed with a visual signal, the device’s safety mechanism protects the patient from inadvertent puncture of the spine.

  • Prevents multiple insertions, saves physician time
  • Improved analgesia/anesthesia success rate
  • Reduced needle placement complications
  • Used in conjunction with Loss of Resistance (LoR) technique


Founded: April 2013
 Business development
Investor: The Trendlines Group, private investors
IP: 1 Chinese patent; 3 patents, National phase
Achievements: Positive validation and verification results, successful animal trials, design freeze

In the Media

  • Omeq in BioTuesdays
  • Israel 21c: Israeli startups pitch to China at virtual Tel Aviv roadshow
  • Globes: Named one of “6 captivating start-ups of 2013”

 The Team

Omeq Medical CEO Lior Margalit presents during a Trendlines Medical U.S. Road Show event in Charleston, South Carolina.

Omeq Medical CEO Lior Margalit presents during a Trendlines Medical U.S. Road Show event in Charleston, South Carolina.

  • Lior Margalit, CEO: R&D and QA engineer, EndyMed, a medical device start-up; naval officer and captain, Israeli Navy; BSc, biomedical engineering, Ben-Gurion University of the Negev
  • Assaf Gur, CTO: Extensive experience in managing early-stage medical device companies; MSc, biomedical engineering, Tel Aviv University; BSc, software engineering and industrial management, Tel Aviv Engineering College
  • Prof. Elon Eisenberg, Medical Adviser: Director of the Institute of Pain Medicine, Rambam Health Care Campus; Associate Professor of Neurology and Pain Medicine, Faculty of Medicine, Technion-Israel Institute of Technology; MD, Sackler School of Medicine, Tel Aviv University; widely published
  • David Gichtin, MD, Medical Adviser: Clinical Associate, Department of Anesthesiology and Critical Care Medicine, Johns Hopkins Medicine Bayview Medical Center; anesthesiologist, Baltimore Pain Management Center; MD, University of Kentucky College of Medicine; member of American Board of Anesthesiology and American Society of Pain Management

Trendlines’ directors: Todd Dollinger, Steve Rhodes

Scientific Advisory Board

  • Boaz Samolsky, MD, Medical Adviser: Anesthesiologist responsible for the Outpatients’ Pain Therapy Centre of the Teaching Hospital of Bologna, Italy; assistant professor; MD (cum laude), University of Bologna Medical School
  • Seth Kaufman, MD, Medical Adviser: Anesthesiologist, specialist in pain management and palliative care; Pain Management and Palliative Care, West Clinic, Memphis, Tennessee; Member, American Board of Anesthesiology; MD, McGill University, Montreal, Canada

Background & Market

Locating the epidural space that surrounds the spinal cord requires extensive physician training and relies heavily on feel. Drugs (“epidurals”) injected into this very narrow space (only 4 millimeters wide) are used for anesthesia and analgesic purposes both during and after surgery.

Inaccurate needle placement occurs in up to 30% of cases, resulting in ineffective drug delivery, multiple insertions, and post-complications such as severe headaches or nerve damage.

In the United States, over 20 million epidural injections are administered annually, with an additional 19 million injections in the rest of the world. Industry leaders control this $1 billion global market with standard epidural kits.


CEO Lior Margalit is interviewed on ILTV.

CEO Lior Margalit presents at the 5th Annual Trendlines Showcase.

Omeq's Lior Margalit presents the novel epidural needle.


Lior Margalit, CEO

Font Resize